Cefuroxime Veterinary Grade API is supplied in two compendial chemical forms: cefuroxime sodium, CAS 56238-63-2, and cefuroxime axetil, CAS 64544-07-6. The sodium salt is the parenteral-grade form used in injections, infusions, intramammary preparations, and irrigation solutions. The axetil ester is the oral-grade prodrug used in tablets, capsules, powders for suspension, granules, and veterinary premixes. No single “veterinary model” exists for cefuroxime because the appropriate specification is determined by the final dosage form. Manufacturer-specific grades are commonly designated as a sterile sodium grade and a micronized axetil grade; these internal model identifiers should be cross-referenced to the certificate of analysis. The sodium grade is released on an anhydrous basis; the axetil grade is released on an anhydrous and solvent-free basis, with the diastereoisomer pair controlled by HPLC. Both forms are second-generation cephalosporins. The axetil-to-cefuroxime molecular weight ratio of 1.203 must be used when expressing oral potency as cefuroxime equivalents. The API is not registered for all food-producing species in all jurisdictions; withdrawal periods for milk, eggs, and edible tissues require target-species residue studies.

What Pharmacopoeial Specifications Govern the Sodium and Axetil API Release?

The sodium salt is controlled against the current Ph. Eur. cefuroxime sodium monograph. HPLC assay is performed by Ph. Eur. 2.2.29 with UV detection at 254 nm; the label claim is expressed as cefuroxime on an anhydrous basis. Typical release acceptance is 98.0%–102.0%. Related substances limits in the sodium monograph set total specified impurities at not more than 3.0% and a single unspecified impurity at not more than 0.5%; the dimer and desacetyl cefuroxime are monitored as degradation markers. Residual solvent limits follow VICH GL18 and Ph. Eur. 2.4.24: acetone is controlled as Class 3 at not more than 5000 ppm, methanol as Class 2 at not more than 3000 ppm, and N,N-dimethylformamide, where used in the axetil synthesis, at not more than 880 ppm. Bacterial endotoxin testing by Ph. Eur. 2.6.14 is applied to parenteral-grade sodium; the limit is dose-derived, and a common parenteral acceptance criterion is not more than 0.10 EU/mg. Sterility testing of the injectable grade follows Ph. Eur. 2.6.1.

The HPLC system suitability test for cefuroxime sodium typically uses a column packed with octadecylsilyl silica gel, 5 µm particle size, 250 mm × 4.6 mm length and internal diameter, with a flow rate of 1.5 mL/min and detection at 254 nm. The resolution between cefuroxime and its principal degradation product must meet monograph-defined acceptance. Sample solutions are prepared at ambient temperature to avoid hydrolytic degradation, and all diluents are degassed to reduce baseline noise. For cefuroxime axetil, the diastereoisomer ratio is expressed as the area percentage of the later-eluting diastereoisomer relative to total axetil; both diastereoisomers are therapeutically inactive until hydrolysed to cefuroxime in the mucosa.

Particle Size, Polymorph Control, and Dry-Granulation Uniformity

For oral solid dosage forms, the particle size distribution of cefuroxime axetil is a critical quality attribute because the prodrug is practically insoluble in water and dissolution may be limited by wetting and surface area. Air-jet milling or pin milling is typically used to reduce the D90 to below 30 µm for low-dose suspension granules and direct-compression tablets; unmicronized axetil may be adequate for higher-dose capsules and premix carriers where content uniformity is less sensitive. Flow behaviour is characterised by Ph. Eur. 2.9.36; a Hausner ratio above 1.35 indicates cohesive powder and generally requires roller compaction or wet granulation. Roller-compaction pressures for cephalosporins are commonly maintained between 4 MPa and 8 MPa, but published data for this specific veterinary-grade configuration is limited and must be generated per formulation. Cefuroxime sodium is not normally micronized for injection because it dissolves readily in water; however, aseptic dry milling may produce a controlled particle fraction for metered dry-powder suspension formulations.

When direct compression is attempted with cefuroxime axetil, the formulation should contain a pregelatinised starch or microcrystalline cellulose diluent with a similar tapped density to avoid segregation during high-speed compression. Tablet presses with forced-feed hoppers can induce densification of fine axetil particles; this is controlled by maintaining relative humidity below 55% in the compression suite. For capsules, the fill weight is determined by the anhydrous assay value, not by a fixed weight of axetil substance, because residual solvent and water content vary between batches. The fill powder should have a bulk density between 0.40 g/mL and 0.60 g/mL to maintain capsule weight variation below 5% relative standard deviation.

Injectable formulations are manufactured as dry powders rather than ready-to-use aqueous solutions because the beta-lactam ring of cefuroxime sodium undergoes hydrolytic degradation in aqueous media. For sterile dry-powder filling, the sodium salt is dissolved, sterile-filtered, and freeze-dried or aseptically crystallised; terminal moist-heat sterilisation is avoided because beta-lactams are thermolabile. The reconstituted solution is usually used immediately or within controlled time because the degradation rate increases with temperature and pH outside the neutral range. The pH of the reconstituted solution is controlled by the monograph; a common target is 6.0–8.5 for a 10% w/v solution. Intravenous admixtures should not be compounded with aminoglycosides such as gentamicin sulfate in the same container because beta-lactams can inactivate aminoglycosides by nucleophilic opening of the lactam ring; separate infusion lines or sequential administration is required. For intramammary preparations, cefuroxime sodium is dispersed in a hydrophobic base to provide prolonged release; homogenisation is carried out under vacuum to prevent high-shear foaming and API oxidation.

For freeze-dried cefuroxime sodium, the lyophilisation cycle is designed around the glass transition and collapse temperature of the formulation matrix. The cake must be elegant, reconstitute within 2 min in water for injection, and leave no visible particles above the pharmacopoeial subvisible limit. Reconstitution time is measured by adding the specified volume of water for injection and gently agitating until complete dissolution; the resulting solution is inspected against black and white backgrounds under 2000–3000 lux illumination. For non-sterile oral solutions and soluble powders, cefuroxime sodium may be dissolved at point of use; these aqueous solutions should be stored between 2 °C and 8 °C and discarded after 24 h unless microbial and chemical stability data support longer storage.

When Cefuroxime Axetil Is Selected for Oral Veterinary Dosage Forms

In tablets and capsules, cefuroxime axetil is often formulated by wet granulation with a binder such as povidone, followed by drying at low inlet air temperature to avoid melting or partial amorphization of the ester. Because the axetil is a prodrug, the tablet must release the intact ester for absorption; hydrolysis to cefuroxime occurs in the intestinal mucosa and plasma by esterases. The dosage strength is expressed in cefuroxime equivalents using the molecular weight ratio 1.203; a 250 mg cefuroxime-equivalent oral dose therefore requires approximately 300 mg of cefuroxime axetil substance. For oral suspension powders, the axetil is blended with sucrose or sorbitol, suspending agents, and dried; the in-use stability of the reconstituted suspension is normally limited to 7–14 days under refrigeration, based on general chapters for oral liquids. In dogs and cats, published data for this specific axetil suspension configuration is limited, and target-species bioavailability studies are required before dose extrapolation from human pharmacokinetic data.

The activity of cefuroxime against anaerobic bacteria is not class-leading; for infections involving Bacteroides fragilis or Clostridium difficile, metronidazole may be required. Because cefuroxime axetil is an oral prodrug, it should not be administered to animals with severe vomiting or reduced gastrointestinal transit, because the ester must remain in the intestinal lumen long enough to be absorbed. In small-animal practice, tablets may need to be divided; scored tablet tooling is preferred because the axetil layer can fracture unevenly if the tablet is deeply concave or insufficiently compressed. Hardness values between 40 N and 80 N are common for cefuroxime axetil film-coated tablets, but published data for this specific veterinary formulation is limited and must be justified by friability testing per Ph. Eur. 2.9.7.

Premix and granule manufacture requires carrier compatibility screening because alkaline mineral carriers and high-moisture organic carriers accelerate beta-lactam hydrolysis. Corncob, ground maize, and lactose-based carriers are preferred to calcium carbonate or bentonite; free water in the carrier should be below 1.5% w/w before addition of cefuroxime axetil. The API is added by geometric dilution in a ribbon blender or plow mixer; batch capacities above 500 kg can show content uniformity drift if the API particle size span exceeds 2.5 and if the carrier bulk density differs from the API by more than 20%. Published data for this specific configuration is limited, so the mixing endpoint should be verified by stratified sampling at 10 positions and HPLC assay. For final solutions, cefuroxime sodium is dissolved in water for injection or buffered vehicles; exposure to strong acids, strong bases, or oxidising agents is incompatible because the cephalosporin nucleus opens readily under these conditions.

Veterinary Spectrum Positioning Relative to Aminopenicillins and Later-Generation Cephalosporins

Compared with amoxicillin trihydrate or ampicillin sodium, cefuroxime sodium is more stable to hydrolysis by certain beta-lactamases produced by Enterobacteriaceae, while retaining activity against methicillin-susceptible staphylococci and Streptococcus spp. It is not effective against methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, or Enterococcus spp.; these exclusions are determined by the absence of PBP2a or the presence of intrinsic efflux and chromosomal AmpC. Ceftiofur sodium and cefquinome sulfate are third- and fourth-generation veterinary cephalosporins with broader Gram-negative coverage in some veterinary pathogens, but cefuroxime may offer a narrower spectrum and a different protein-binding profile for selected companion-animal and non-food-animal applications. Cefuroxime axetil is absorbed orally, whereas ceftiofur sodium is administered by injection; this route difference is decisive when oral treatment of small groups of dogs or cats is required.

Regulatory status varies by country; veterinary approval, maximum residue limits for food-producing animals, and withdrawal periods must be confirmed against national compendial monographs and Codex Alimentarius decisions before use. Cefuroxime is not a first-line agent for every beta-lactam-susceptible veterinary infection; its selection should be based on susceptibility testing, tissue distribution, and the route of administration available for the target species.

Differences between cefuroxime sodium and axetil form should be specified on the certificate of analysis, not only by assay. The sodium form must include free-water content by Ph. Eur. 2.5.12 and, for sterile grade, sterility by membrane filtration. The axetil form must include diastereoisomer ratio by HPLC because the two diastereoisomers can exhibit different solubility and dissolution behaviour. For all dosage forms, avoid storage above 25 °C, protect from moisture, and do not blend with alkaline lubricants such as magnesium stearate at high concentration without compatibility data, because the lubricant’s alkaline pH can increase cefuroxime ester hydrolysis during tablet compression. For premix and granule operations, batch records should record blending time, carrier moisture, and stratified sampling results; the absence of these data may prevent batch release under EU GMP Part II or ICH Q7 for API-derived veterinary medicinal products.